Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
BMJ Open ; 14(6): e084847, 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38830735

ABSTRACT

INTRODUCTION: Tranexamic acid (TXA) is an inexpensive and widely available medication that reduces blood loss and red blood cell (RBC) transfusion in cardiac and orthopaedic surgeries. While the use of TXA in these surgeries is routine, its efficacy and safety in other surgeries, including oncologic surgeries, with comparable rates of transfusion are uncertain. Our primary objective is to evaluate whether a hospital-level policy implementation of routine TXA use in patients undergoing major non-cardiac surgery reduces RBC transfusion without increasing thrombotic risk. METHODS AND ANALYSIS: A pragmatic, registry-based, blinded, cluster-crossover randomised controlled trial at 10 Canadian sites, enrolling patients undergoing non-cardiac surgeries at high risk for RBC transfusion. Sites are randomised in 4-week intervals to a hospital policy of intraoperative TXA or matching placebo. TXA is administered as 1 g at skin incision, followed by an additional 1 g prior to skin closure. Coprimary outcomes are (1) effectiveness, evaluated as the proportion of patients transfused RBCs during hospital admission and (2) safety, evaluated as the proportion of patients diagnosed with venous thromboembolism within 90 days. Secondary outcomes include: (1) transfusion: number of RBC units transfused (both at a hospital and patient level); (2) safety: in-hospital diagnoses of myocardial infarction, stroke, deep vein thrombosis or pulmonary embolism; (3) clinical: hospital length of stay, intensive care unit admission, hospital survival, 90-day survival and the number of days alive and out of hospital to day 30; and (4) compliance: the proportion of enrolled patients who receive a minimum of one dose of the study intervention. ETHICS AND DISSEMINATION: Institutional research ethics board approval has been obtained at all sites. At the completion of the trial, a plain language summary of the results will be posted on the trial website and distributed in the lay press. Our trial results will be published in a peer-reviewed scientific journal. TRIAL REGISTRATION NUMBER: NCT04803747.


Subject(s)
Antifibrinolytic Agents , Tranexamic Acid , Humans , Tranexamic Acid/therapeutic use , Tranexamic Acid/administration & dosage , Antifibrinolytic Agents/therapeutic use , Antifibrinolytic Agents/administration & dosage , Canada , Blood Loss, Surgical/prevention & control , Cross-Over Studies , Erythrocyte Transfusion , Organizational Policy
2.
ScientificWorldJournal ; 2013: 396404, 2013 Nov 12.
Article in English | MEDLINE | ID: mdl-24324371

ABSTRACT

BACKGROUND: Perioperative aneurysm rupture (PAR) is one of the most dreaded complications of intracranial aneurysms, and approximately 80% of nontraumatic SAHs are related to such PAR aneurysms. The literature is currently scant and even controversial regarding the issues of various contributory factors on different phases of perioperative period. Thus this paper highlights the current understanding of various risk factors, variables, and outcomes in relation to PAR and try to summarize the current knowledge. METHOD: We have performed a PubMed search (1 January 1991-31 December 2012) using search terms including "cerebral aneurysm," "intracranial aneurysm," and "intraoperative/perioperative rupture." RESULTS: Various risk factors are summarized in relation to different phases of perioperative period and their relationship with outcome is also highlighted. There exist many well-known preoperative variables which are responsible for the highest percentage of PAR. The role of other variables in the intraoperative/postoperative period is not well known; however, these factors may have important contributory roles in aneurysm rupture. Preoperative variables mainly include natural course (age, gender, and familial history) as well as the pathophysiological factors (size, type, location, comorbidities, and procedure). Previously ruptured aneurysm is associated with rupture in all the phases of perioperative period. On the other hand intraoperative/postoperative variables usually depend upon anesthesia and surgery related factors. Intraoperative rupture during predissection phase is associated with poor outcome while intraoperative rupture at any step during embolization procedure imposes poor outcome. CONCLUSION: We have tried to create such an initial categorization but know that we cannot scale according to its clinical importance. Thorough understanding of various risk factors and other variables associated with PAR will assist in better clinical management as well as patient care in this group and will give insight into the development and prevention of such a catastrophic complication in these patients.


Subject(s)
Intracranial Aneurysm/complications , Intracranial Aneurysm/epidemiology , Intracranial Aneurysm/physiopathology , Intracranial Hemorrhages/epidemiology , Intracranial Hemorrhages/etiology , Intracranial Hemorrhages/pathology , Perioperative Period/statistics & numerical data , Humans , Intracranial Aneurysm/surgery , PubMed , Risk Factors
3.
Can J Anaesth ; 60(11): 1139-55, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24129743

ABSTRACT

PURPOSE: The complexity of neurosurgical procedures and their interactions with maternal and fetal physiologies are key factors in determining the overall maternal and fetal outcome. The literature and guidelines provide only partial information regarding the standard of care in these cases. The purpose of this Continuing Professional Development module is to review the issues related to common neurosurgical conditions and their optimal anesthetic management. PRINCIPAL FINDINGS: The most common neurosurgical conditions found in pregnancy include brain tumours, cerebrovascular diseases, spinal pathologies, and neurotrauma. Though rare, these conditions and related procedures may affect maternal and fetal outcome. Maternal considerations should be given priority in cases of emergent surgeries irrespective of trimester. In the early first trimester, risk of fetal loss and congenital malformation are substantial; hence, proper counselling should be given to the mother with special emphasis on therapeutic abortion. When indicated, anticonvulsants should be started as early as possible and continued throughout pregnancy. Surgical procedures can be performed with relative safety during the second trimester and early third trimester. After 34 weeks, delivery seems to be the first choice, and the role of regional anesthesia in this situation should be carefully planned after proper review of neurosurgical pathology and maternal condition. During acute neurological deterioration, however, Cesarean delivery under general anesthesia should be anticipated. CONCLUSION: A multidisciplinary approach with good communication amongst all team members certainly plays a crucial role for successful management of such cases.


Subject(s)
Nervous System Diseases/surgery , Neurosurgical Procedures/methods , Pregnancy Complications/surgery , Anesthesia, General/methods , Cesarean Section/methods , Communication , Female , Humans , Nervous System Diseases/physiopathology , Patient Care Team/organization & administration , Pregnancy , Pregnancy Complications/physiopathology , Pregnancy Outcome , Pregnancy Trimesters
4.
J Anaesthesiol Clin Pharmacol ; 29(3): 299-302, 2013 Jul.
Article in English | MEDLINE | ID: mdl-24106350

ABSTRACT

Trauma is a leading cause of death worldwide and traumatic brain injury is one of the commonest injuries associated with it. The need for urgent resuscitation is warranted for prevention of secondary insult to brain. However, the choice of fluid in such cases is still a matter of conflict. The literature does not provide enough data pertaining to role of colloids in head injury patients. In this article, we have tried to explore the present role of colloid resuscitation in patient with head injury.

5.
Saudi J Anaesth ; 7(2): 187-90, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23956721

ABSTRACT

The current era has adopted many new innovations in nearly every aspect of management of subarachnoid hemorrhage (SAH); however, the neurological outcome has still not changed significantly. These major therapeutic advances mainly addressed the two most important sequels of the SAH-vasospasm and re-bleed. Thus, there is a possibility of some different pathophysiological mechanism that would be responsible for causing poor outcome in these patients. In this article, we have tried to compile the current role of this different yet potentially treatable pathophysiological mechanism in post-SAH patients. The main pathophysiological mechanism for the development of early brain injury (EBI) is the apoptotic pathways. The macro-mechanism includes increased intracranial pressure, disruption of the blood-brain barrier, and finally global ischemia. Most of the treatment strategies are still in the experimental phase. Although the role of EBI following SAH is now well established, the treatment modalities for human patients are yet to be testified.

6.
Saudi J Anaesth ; 6(4): 408-11, 2012.
Article in English | MEDLINE | ID: mdl-23493049

ABSTRACT

Neuroanaesthetic considerations in non neurosurgical cases are utmost important for the optimal management of such cases. These considerations become even more challenging in patients undergoing emergency surgeries. We have highlighted the neuroanesthetic considerations for three broad categories. The two most important considerations in this type of surgery will be the avoidance of secondary brain insult and maintenance of optimal cerebral perfusion pressure.

SELECTION OF CITATIONS
SEARCH DETAIL
...